The cannabinoid receptor 1 gene (CNR1) is implicated in adipocyte function.
T HE CANNABINOID-1 (CB1) RECEPTOR, encoded by
the CNR1 gene, is most abundantly expressed in the central nervous system but also in several peripheral organs including liver, muscle, and adipose tissue, whereas the CB2 receptor is restricted to immune cells (1) . Both CB receptors belong to the family of G-coupled receptors that after ligand binding modulates the activity of various cell-signaling cascades including adenylate cyclase-and mitogen-activated protein kinase-related events (2) . The observation of increased food intake in rodents given cannabinoid receptor ligands (3) together with the generation of a hypophagic and lean phenotype in mice lacking the CB1 receptor implicates a role of the endocannabinoid system in the treatment of diet-induced obesity (4) . Moreover, the findings of increased adipocyte lipoprotein lipase activity (4) and reduced adiponectin, ADIPOQ, mRNA expression (5) and effects on lipolysis and energy expenditure (6) upon CB1 receptor activation also suggest a fat-cell-specific role of the endocannabinoid system. The human CNR1 gene is expressed in both omental and sc adipocytes at both the mRNA and protein levels and found to mediate an increase in intracellular cAMP levels after stimulation (7) .
Whether adipose tissue CB1 receptors are important in the pathogenesis of obesity and associated metabolic disorders is unknown. In recent studies, obesity was found to be associated with increased levels of endocannabinoids but decreased amounts of CNR1 mRNA (8, 9) . Here, we investigated human CNR1 mRNA levels from both abdominal sc and omental adipose tissue in relation to clinical variables, fat cell function, and adiponectin expression.
Subjects and Methods Subjects
The Hospital's committee on ethics approved the study. All subjects were apparently healthy and free of medication and ate a standard Swedish diet. Two separate cohorts were used. Cohort 1 was composed of 80 obese women with body mass index (BMI) of 31-53 kg/m 2 (age, 21-63 yr) and 16 lean women with BMI of 20 -24 kg/m 2 (age, 26 -52 yr). At approximately 0730 h after an overnight fast, a venous blood sample was obtained for analyses of plasma levels of glucose, insulin, triglycerides, cholesterol, high-density lipoprotein cholesterol, free fatty acids, and adiponectin. The analyses were performed by the hospital's accredited chemistry laboratory except for serum levels of adiponectin, which were measured using an RIA method (Linco Research, Inc., St. Charles, MO) and were expressed as micrograms per milliliter. Insulin sensitivity was calculated from the homeostasis model assessment algorithm based on plasma glucose and plasma insulin (plasma insulin ϫ plasma glucose/22.5). Systolic and diastolic blood pressures were measured in the supine position after 15 min of rest. Thereafter, an adipose sample (1-4 g) was obtained by needle biopsy from the abdominal sc area under local anesthesia (10) . This tissue (1 g) was frozen in liquid nitrogen, kept frozen at Ϫ70 C, and used for subsequent mRNA analysis (see below). In obese subjects, there was adipose tissue available also for fat cell lipolysis and lipogenesis studies and in 30 obese subjects also for analysis of adipose tissue adiponectin secretion (see below). 
Fat cell lipolysis and lipogenesis
The lipolysis experiments were performed as described (11) . In brief, fat cells were incubated in the absence (basal) or presence of increasing concentrations of either noradrenaline (a nonselective ␤-and ␣2-adrenoceptor agonist), dobutamine (a selective ␤1-adrenoceptor agonist), or terbutaline (a selective ␤2-adrenoceptor agonist). After 2 h incubation, the medium was removed for measurement of glycerol, a quantitative marker for lipolysis. In studying lipogenesis, we used an indirect method, which is described in detail elsewhere (12) . The method used reflects glucose transport because, at micromolar glucose concentrations, glucose transport is the rate-limiting step for lipogenesis in human fat cells as discussed (12) .
Adipose tissue adiponectin secretion
In 30 obese subjects of cohort 1, there was tissue available also for measurement of sc adipose tissue adiponectin secretion. The adipose tissue was cut into small pieces (10 -25 mg) and then incubated at 37 C (3.0 ml medium/300 mg tissue) in a medium consisting of sterile KrebsRinger phosphate buffer (pH 7.4), endotoxin-free BSA (4 g/100 ml), and glucose (1 mg/ml), with air as the gas phase. After a 2-h incubation, a 1-ml aliquot of medium was removed and stored at Ϫ70 C for subsequent analysis of adiponectin using the RIA described above.
mRNA analysis
cDNA synthesis and quantitative real-time PCR was performed as described (13) . CNR1 mRNA was quantified using TaqMan (Hs00275009_s1; Applied Biosystems, Foster City, CA). Low-density lipoprotein receptor-related protein, LRP10, mRNA was quantified using either TaqMan (Hs00204094_m1) as a reference for CNR1 or SYBR Green-based real-time PCR (Bio-Rad Laboratories Inc., Hercules, CA) using primers 5Ј-GATGGAGGCTGAGATTGTG-3Ј (sense) and 5Ј-GAGTCATATCCTGGCGTAAG-3Ј (antisense) as reference for ADI-POQ. ADIPOQ mRNA (NM_004797) was quantified using SYBR Greenbased real-time PCR with primers 5Ј-GGTCTCGAACTCCTGGCCTA-3Ј (sense) and 5Ј-TGAGATATCGACTGGGCATGGT-3Ј (antisense). Fatty acid amide hydrolase, FAAH, and monoglyceride lipase, MGLL, mRNA were quantified using TaqMan (Hs_01038659 and Hs_00996007, respectively). The C t values were normalized to levels of LRP10 mRNA and data presented as arbitrary units. LRP10 was used as a reference gene based on a recent comparative study identifying LRP10 as the gene with the least variation in expression levels in human adipose tissue (14) .
Ct-values for CNR1 detection were 30.5 Ϯ 0.6 (sc) and 30.9 Ϯ 0.7 (omental).
Statistical analysis
Parameter distributions were normalized when necessary by logarithm 10 transformation before statistical comparison. Values are mean Ϯ sd. The Student's unpaired t test, ANOVA, single regression analysis, and 2 analysis were used for statistical evaluation. A P value less than 0.05 was considered statistically significant. The analyses were performed using StatView version 6.0 (Stata Corp., College Station, TX).
Results
No difference in CNR1 mRNA levels between obese and nonobese subjects in sc (2.4 Ϯ 0.8 vs. 2.4 Ϯ 1.0, P ϭ 0.99) or omental (3.9 Ϯ 1.6 vs. 4.2 Ϯ 2.2, P ϭ 0.60) adipose tissue was found. In contrast, sc (2.4 Ϯ 0.7 vs. 3.2 Ϯ 0.7, P ϭ 0.0003) and omental (2.2 Ϯ 0.7 vs. 2.8 Ϯ 0.9, P ϭ 0.0009) FAAH mRNA levels were reduced in obesity, whereas omental (3.8 Ϯ 1.2 vs. 4.7 Ϯ 1.9, P ϭ 0.008) but not sc (2.9 Ϯ 1.3 vs. 3.4 Ϯ 1.6, P ϭ 0.21) MGLL mRNA levels were down-regulated in obese subjects. No significant correlations between CNR1 and FAAH or MGLL mRNA levels were found in either sc or omental adipose tissue (data not shown).
After dividing the adipose CNR1 mRNA levels from obese subjects into tertiles based on high, intermediate, and low levels, respectively, no difference in clinical or metabolic variables was found between expression levels of sc or omental adipose tissue CNR1 mRNA (Table 1) .
With respect to adipocyte function, there was no difference in sc basal or maximal lipolysis induced by noradrenaline, dobutamine, or terbutaline between tertiles of CNR1 mRNA (Table 2) . Also, EC 50 (representing adrenoceptor sensitivity) for noradrenaline-, dobutamine-, and terbutaline-induced lipolysis were not different between levels of CNR1 mRNA. The results from omental fat cell lipolysis displayed a similar pattern. Results from lipogenesis experiments revealed that basal and maximal insulin-induced lipogenesis as well as EC 50 for insulin receptor agonist activation were similar between tertiles of CNR1 mRNA (Table 2) .
No association between mRNA expression of CNR1 and ADIPOQ was found in either sc or omental adipose tissue (Fig. 1) . We also investigated the relation between serum and adipose secretion levels of adiponectin and sc adipose tissue CNR1 gene expression (cohort 1). As seen in Fig. 2 , there were no associations between adiponectin serum or secretion levels and CNR1 mRNA.
Discussion
A principal function of adipose tissue is to store or release energy depending on nutritional status. These processes, termed lipogenesis and lipolysis, respectively, are subject to intense hormonal regulation (15, 16) . Although it has been shown that the endocannabinoids may also play an important role in fat cell function (17) , very few data have been presented regarding the pathophysiological significance of the endocannabinoid system in obesity and insulin resistance development.
To further explore this issue, we investigated the sc and omental adipose tissue CNR1 gene expression in relation to obesity and various clinical and metabolic variables as well as both lipogenesis and lipolysis. In contrast to previous studies, in which both a reduced (8, 9) and increased (5) expression of CNR1 mRNA in obesity has been demonstrated, we found no difference in adipose tissue CNR1 mRNA levels between obese and lean subjects. Moreover, there was no association between either sc or omental adipose CNR1 gene expression and clinical and metabolic variables. The reason for these conflicting results is unknown. Nevertheless, the results from adipocyte functional studies displayed a similar pattern; the sc and omental fat cell function was not different in subjects with either a high or a low CNR1 gene expression level. However, we measured lipogenesis in sc adipocytes only. Thus, we cannot exclude that CNR1 mRNA expression may be related to omental adipocyte lipogenesis given the recent finding of positive visceral fat CNR1 and SREB1c mRNA correlation (9) . Unfortunately, there was not enough tissue available for analysis of protein levels of CNR1 to confirm the mRNA data. Nevertheless, although the present results are based on associative data only, they do not speak in favor of a clear role of the CNR1 gene in fat cell function or metabolic disease development. Interestingly, we found decreased adipose mRNA levels of the endocannabinoid-degrading enzymes in obesity, at least for FAAH. This finding is in line with the report by Engeli et al. (8) and may at least in part be a mechanistic explanation for the observed increase in circulating endocannabinoids seen in obesity (8, 9) .
It has been suggested that the endocannabinoids may exert their action in adipocytes also by reducing the expression of adiponectin. In CNR1 knockout mice, an increased adipose tissue mRNA level of ADIPOQ was demonstrated (5) , and in murine cell lines, ADIPOQ gene expression was reduced after CB1 receptor activation (18, 19) but increased after CB1 receptor antagonism (19) . In contrast, in a recent weight reduction study, no difference in serum adiponectin levels was found between rats treated with CB1 receptor antagonist or given a low-calorie diet, despite a similar degree of weight loss (20) . In accordance with the latter study, the present negative data do not speak in favor of a clear association between human adipose CNR1 expression and ADIPOQ levels in man.
In conclusion, we found no relation between sc or omental adipose tissue gene expression of CNR1 and various clinical variables. Moreover, fat cell function measured as lipogenesis and lipolysis and various measures of ADIPOQ expression were not associated with adipose CNR1 mRNA. Consequently, these data do not provide evidence for a consistent role of CNR1 in human adipocyte function. 
